DOP2002000445A - Composiciones farmaceuticas de amlodipina y atorvastatina - Google Patents
Composiciones farmaceuticas de amlodipina y atorvastatinaInfo
- Publication number
- DOP2002000445A DOP2002000445A DO2002000445A DO2002000445A DOP2002000445A DO P2002000445 A DOP2002000445 A DO P2002000445A DO 2002000445 A DO2002000445 A DO 2002000445A DO 2002000445 A DO2002000445 A DO 2002000445A DO P2002000445 A DOP2002000445 A DO P2002000445A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- atorvastatin
- compositions
- pharmaceutically acceptable
- acceptable salts
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Una composición farmacéutica que comprende dos componentes: a) un componente que comprende una granulación de atorvastatina o sus sales farmacéuticamente aceptables y un vehículo que incluye un agente alcalinizante que forma un pH mayor 5; y b) un segundo componente que comprende amlopidina o sus sales farmacéuticamente aceptables y un vehículo que excluye un agente alcalinizante que forma un pH mayor que 5, en donde los dos componentes se combinan para formar una composición final para una forma de dosificación sólida; se describen también métodos para preparar las composiciones, estuches de ensayo para contener tales composiciones y un método para tratar angina de pecho, aterosclerosis, hipertensión combinada e hiperlipidemia y/o hipercolesterolemia, y síntomas de riesgo cardíaco usando una cantidad terapéuticamente eficaz de la composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30913301P | 2001-07-31 | 2001-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2002000445A true DOP2002000445A (es) | 2003-01-31 |
Family
ID=23196829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2002000445A DOP2002000445A (es) | 2001-07-31 | 2002-07-30 | Composiciones farmaceuticas de amlodipina y atorvastatina |
Country Status (47)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524615B2 (en) * | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| BRPI0513396A (pt) * | 2004-07-16 | 2008-05-06 | Lek Pharmaceuticals | produtos de degradação oxidativa de atorvastatina de cálcio |
| KR100923939B1 (ko) * | 2004-09-28 | 2009-10-29 | 테바 파마슈티컬 인더스트리즈 리미티드 | 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법 |
| US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| US20080305158A1 (en) * | 2004-12-28 | 2008-12-11 | Ranbaxy Laboratories Limited | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine |
| US10130624B2 (en) * | 2005-03-15 | 2018-11-20 | Lupin Limited | Pharmaceutical compositions of amlodipine and benazepril |
| US8124622B2 (en) | 2006-03-29 | 2012-02-28 | Kowa Co., Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| DE102006033723A1 (de) * | 2006-07-21 | 2008-01-24 | Bayer Technology Services Gmbh | Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe |
| KR100793321B1 (ko) * | 2006-11-29 | 2008-01-11 | 사회복지법인 삼성생명공익재단 | 후각장애 치료 및 예방용 조성물 |
| CN101433539A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和他汀类药物的治疗组合物 |
| EP2070520A1 (en) | 2007-12-11 | 2009-06-17 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media |
| WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
| ES2377552T3 (es) | 2008-09-17 | 2012-03-28 | Helm Ag | Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda |
| EP2341773A4 (en) * | 2008-09-24 | 2012-03-07 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN |
| WO2011152803A1 (en) * | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Water soluble formulation comprising a combination of amlodipine and a statin |
| EP2749281B1 (en) | 2011-08-26 | 2018-03-28 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
| JP2013231011A (ja) * | 2012-05-01 | 2013-11-14 | Sawai Pharmaceutical Co Ltd | アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠 |
| KR20140030505A (ko) * | 2012-08-31 | 2014-03-12 | 한미약품 주식회사 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| KR20140028971A (ko) | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| US10350171B2 (en) * | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| CN109180701A (zh) * | 2018-09-07 | 2019-01-11 | 中国药科大学 | 一种化合物2016a0c1药物组合物的共无定形物 |
| KR102042626B1 (ko) | 2019-06-26 | 2019-11-11 | 한미약품 주식회사 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| JP7660352B2 (ja) * | 2019-09-02 | 2025-04-11 | 日本ジェネリック株式会社 | アトルバスタチンカルシウム水和物及びエゼチミブを含む錠剤 |
| CN111689922B (zh) * | 2020-07-17 | 2022-03-15 | 江西施美药业股份有限公司 | 一种苯磺酸左旋氨氯地平环合杂质的合成方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| ATE178794T1 (de) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
| US5385929A (en) * | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
| SI9500173B (sl) * | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| DK1148049T3 (da) * | 1995-07-17 | 2005-03-29 | Warner Lambert Co | Krystallinsk [R-(R*,R*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre-hemicalciumsalt (ATORVASTATIN) |
| NZ319906A (en) * | 1995-11-02 | 2000-02-28 | Warner Lambert Co | Method of preparing a pharmaceutical composition for regulating lipid concentration comprising using an acyl-CoA cholesterol O-acyltransferase inhibitor and an HMG-CoA reductase inhibitor |
| IL133957A0 (en) * | 1997-08-29 | 2001-04-30 | Pfizer Prod Inc | Combination therapy comprising amlodipine and a statin compound |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| EP1047421A2 (en) * | 1997-11-25 | 2000-11-02 | Warner-Lambert Company | Inhibition of lipoprotein oxidation |
| CA2370639A1 (en) * | 1999-04-23 | 2000-11-02 | R. Preston Mason | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
| HN2000000050A (es) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
| AU2001283085A1 (en) * | 2000-08-04 | 2002-02-18 | R. Preston Mason | Synergistic effect of amlodipine and atorvastatin |
-
2002
- 2002-07-25 PE PE2002000666A patent/PE20030324A1/es not_active Application Discontinuation
- 2002-07-25 US US10/202,706 patent/US20030114497A1/en not_active Abandoned
- 2002-07-26 NI NI200200095A patent/NI200200095A/es unknown
- 2002-07-26 GT GT200200158A patent/GT200200158A/es unknown
- 2002-07-29 ES ES02751483T patent/ES2298381T3/es not_active Expired - Lifetime
- 2002-07-29 DE DE60225014T patent/DE60225014T2/de not_active Expired - Fee Related
- 2002-07-29 MY MYPI20022844A patent/MY137519A/en unknown
- 2002-07-29 HN HN2002000198A patent/HN2002000198A/es unknown
- 2002-07-29 PT PT02751483T patent/PT1411923E/pt unknown
- 2002-07-29 JP JP2003516513A patent/JP4020863B2/ja not_active Expired - Fee Related
- 2002-07-29 AR ARP020102852A patent/AR034925A1/es not_active Application Discontinuation
- 2002-07-29 DK DK02751483T patent/DK1411923T3/da active
- 2002-07-29 AP APAP/P/2004/002963A patent/AP1745A/en active
- 2002-07-29 CA CA002444554A patent/CA2444554C/en not_active Expired - Fee Related
- 2002-07-29 IL IL15944002A patent/IL159440A0/xx unknown
- 2002-07-29 RS YU5304A patent/RS5304A/sr unknown
- 2002-07-29 GE GE5399A patent/GEP20063926B/en unknown
- 2002-07-29 EP EP02751483A patent/EP1411923B1/en not_active Expired - Lifetime
- 2002-07-29 CN CNA028150406A patent/CN1617717A/zh active Pending
- 2002-07-29 OA OA1200400009A patent/OA13300A/en unknown
- 2002-07-29 EA EA200400028A patent/EA006998B1/ru not_active IP Right Cessation
- 2002-07-29 HR HR20040067A patent/HRP20040067A2/xx not_active Application Discontinuation
- 2002-07-29 UA UA20031212503A patent/UA79750C2/uk unknown
- 2002-07-29 KR KR1020067008620A patent/KR100674762B1/ko not_active Expired - Fee Related
- 2002-07-29 NZ NZ530247A patent/NZ530247A/en unknown
- 2002-07-29 MX MXPA04000270A patent/MXPA04000270A/es active IP Right Grant
- 2002-07-29 WO PCT/IB2002/002988 patent/WO2003011283A1/en not_active Ceased
- 2002-07-29 EP EP07110366A patent/EP1852116A1/en not_active Withdrawn
- 2002-07-29 CN CNA2007101601072A patent/CN101185646A/zh active Pending
- 2002-07-29 PL PL02368519A patent/PL368519A1/xx not_active Application Discontinuation
- 2002-07-29 KR KR10-2004-7001522A patent/KR20040032148A/ko not_active Ceased
- 2002-07-29 HU HU0401569A patent/HUP0401569A2/hu unknown
- 2002-07-29 AT AT02751483T patent/ATE385793T1/de not_active IP Right Cessation
- 2002-07-29 SG SG200601276-9A patent/SG143982A1/en unknown
- 2002-07-29 AU AU2002355680A patent/AU2002355680B2/en not_active Ceased
- 2002-07-29 BR BR0211548-4A patent/BR0211548A/pt not_active IP Right Cessation
- 2002-07-30 UY UY27402A patent/UY27402A1/es not_active Application Discontinuation
- 2002-07-30 PY PY200200218256A patent/PY0218256A/es unknown
- 2002-07-30 PA PA20028551701A patent/PA8551701A1/es unknown
- 2002-07-30 SV SV2002001189A patent/SV2003001189A/es active IP Right Grant
- 2002-07-30 DO DO2002000445A patent/DOP2002000445A/es unknown
-
2003
- 2003-12-22 IS IS7089A patent/IS7089A/is unknown
- 2003-12-31 CO CO03113785A patent/CO5540287A2/es not_active Application Discontinuation
-
2004
- 2004-01-06 CR CR7219A patent/CR7219A/es not_active Application Discontinuation
- 2004-01-21 MA MA27495A patent/MA27052A1/fr unknown
- 2004-01-27 ZA ZA200400659A patent/ZA200400659B/en unknown
- 2004-01-29 NO NO20040405A patent/NO20040405L/no not_active Application Discontinuation
- 2004-01-30 EC EC2004004965A patent/ECSP044965A/es unknown
- 2004-01-30 TN TNP2004000022A patent/TNSN04022A1/fr unknown
- 2004-10-19 US US10/968,314 patent/US20050107446A1/en not_active Abandoned
-
2007
- 2007-02-14 JP JP2007034002A patent/JP2007153908A/ja not_active Withdrawn
- 2007-08-01 JP JP2007200684A patent/JP2007314566A/ja not_active Withdrawn
-
2008
- 2008-03-17 CY CY20081100299T patent/CY1107245T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2002000445A (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
| TR200000561T2 (tr) | Amlodipin ve atorvastatin içeren tedavisel bileşikler. | |
| UY25155A1 (es) | Composiciones farmacéuticas conteniendo atorvastatina y un agente antihipertensivo | |
| AR017514A1 (es) | Composicion farmaceutica, una primera composicion para usarse como una segunda composicion, un estuche, procedimiento para tratar un mamifero | |
| AR030190A1 (es) | Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo | |
| FI973518A7 (fi) | Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa | |
| AR015487A1 (es) | Uso de un compuesto de colesterol hidroxilado como agente reductor para preparar una composicion farmaceutica de utilidad en un metodo para inhibirla oxidacion de las lipoproteinas en un mamifero. | |
| TR199800631A2 (xx) | Ecza form�lasyonu. | |
| UA44254C2 (uk) | Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція | |
| UY26163A1 (es) | Sal mutua de amlodipino y atorvastatina | |
| EE200200591A (et) | Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks | |
| AR022344A1 (es) | Profarmacos mutuos de amlodipino y atorvastatina | |
| BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
| BR9811348A (pt) | Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas. | |
| EE200100219A (et) | (+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli estrid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
| BR9807312B1 (pt) | Derivados de (4-piperidinil)-1h-2-benzopirano úteis como agentes antipsicóticos, composição farmacêutica e processo para a preparação dos referidos derivados | |
| EE05038B1 (et) | B-grupi streptogramiinide derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja segu | |
| ECSP982646A (es) | Combinaciones terapeuticas | |
| ECSP003497A (es) | Sal mutua de amlodipino y atorvastatina | |
| ECSP982645A (es) | Terapia de combinacion | |
| ECSP003493A (es) | Profarmacos mutuos de amlodipino y atorvastatina |